Apixaban

Chemical formula: C₂₅H₂₅N₅O₄  Molecular mass: 459.497 g/mol  PubChem compound: 10182969

Therapeutic indications

Apixaban is indicated for:

Prevention of venous thromboembolic events in total hip replacement surgery or total knee replacement surgery

Population group: only adults (18 years old or older)

Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF)

Population group: only adults (18 years old or older)

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)

Population group: only adults (18 years old or older)

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Apixaban is contraindicated in the following cases:

Anticoagulants

Antithrombotic agents

Active clinically significant bleeding

Bleeding

Lesion or condition, if considered a significant risk factor for major bleeding

at least one of
Gastrointestinal ulcer
Spinal injury
Traumatic brain injury
Intracranial hemorrhage
Operation on brain
Operative procedure on spinal structures
Esophageal varices
Aneurysm
Congenital vascular malformation

Severe hepatic impairment

Hepatic failure stage IV

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: ELIQUIS Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈